Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference January 4, 2021
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome December 11, 2020
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results November 10, 2020
There are currently no events to display.
Developing novel therapeutics for the treatment of rare diseases.